Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BR 101801

Next Previous
Search
Drug Profile

BR 101801

Alternative Names: BR-101801

Latest Information Update: 06 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA-activated protein kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies
  • Preclinical Colorectal cancer

Most Recent Events

  • 06 Jan 2025 Chemical structure information added.
  • 09 Dec 2023 Updated efficacy and adverse event data from a phase I trial in Hematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 09 Dec 2023 Boryung Pharmaceutical plans to initiate a phase II trial for peripheral T cell lymphoma and Nodal T-follicular helper cell lymphomain

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top